Dissertation committee:
1. Σαφιολέας Μιχαήλ, Καθηγητής, Ιατρική, ΕΚΠΑ
2. Μπάμιας Αριστοτέλης, Καθηγητής, Ιατρική, ΕΚΠΑ
3. Αρκαδόπουλος Νικόλαος, Καθηγητής, Ιατρική, ΕΚΠΑ
4. Κόντζογλου Κωνσταντίνος, Καθηγητής, Ιατρική, ΕΚΠΑ
5. Χρυσοφός Μιχαήλ, Καθηγητής, Ιατρική, ΕΚΠΑ
6. Παπατσώρης Αθανάσιος, Αν. Καθηγητής, Ιατρική, ΕΚΠΑ
7. Δελλής Αθανάσιος, Αν. Καθηγητής, Ιατρική, ΕΚΠΑ
Summary:
The purpose of this doctoral thesis is:
• Investigation of hormonal profile disorders in patients with metastatic renal cancer under targeted therapies
• the association of these disorders with response to treatment and prognosis of patients.
Our patients were treated with protein tyrosine kinase inhibitors and m-Tor (mammalian target of rapamycin) inhibitors.
The following hormones were measured during this study: thyroid hormone (TSH), free thyroxine (fT4) as well as thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and TSH receptor antibodies (TR-Ab). In addition, corticosteroid inhibitory hormone (ACTH), follicular hormone (FSH), luteinizing hormone (LH), estradiol, testosterone, prolactin (PRL), parathyroid hormone (PTH), calcitonin, (GH) and morning cortisol. All serum samples were analyzed by Immunoradiometric Methods (IRMA).
Subsequent analysis and interpretation of hormone levels and their association with patient survival followed.
Keywords:
Kidney cancer, Sunitinib, Hormone levels, TKIs, mTor inhibitors
